A new eruption of bullous pemphigoid following mRNA COVID-19 vaccination

Daines, Bryan; Madigan, Lauren M.; Vitale, Patricia A; Khalighi, Mazdak A.; Innes, Matthew

doi:10.5070/d328458525

Cited by 3 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the new onset group, BP patients with limited involvement were treated with topical corticosteroids, while those with more extensive involvements received a variety of systemic immunomodulators, including corticosteroids, doxycycline, nicotinamide, methotrexate, azathioprine, cyclosporine, mycophenolate mofetil, cyclophosphamide, dapsone, colchicine, or hydroxychloroquine [5,6,14,15,28,31,32,35,38,39,[42][43][44][45]49,51,53,56,[70][71][72][73]75,77,82,86,87,92,93]. DPP-4 inhibitors were suspended in patients using these medications [34,44,45,48].…”

Section: Treatment and Outcomes For New-onset Aibd Or Aibd Flaresmentioning

confidence: 99%

New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review

Wu,

Huang,

Wang

et al. 2024

Vaccines

View full text Add to dashboard Cite

Background: Cases of autoimmune bullous dermatosis (AIBD) have been reported following COVID-19 vaccination. Objective: We aimed to provide an overview of clinical characteristics, treatments, and outcomes of AIBDs following COVID-19 vaccination. Methods: We conducted a systematic review and searched the Embase, Cochrane Library, and Medline databases from their inception to 27 March 2024. We included all studies reporting ≥ 1 patient who developed new-onset AIBD or experienced flare of AIBD following at least one dose of any COVID-19 vaccine. Results: We included 98 studies with 229 patients in the new-onset group and 216 in the flare group. Among the new-onset cases, bullous pemphigoid (BP) was the most frequently reported subtype. Notably, mRNA vaccines were commonly associated with the development of AIBD. Regarding the flare group, pemphigus was the most frequently reported subtype, with the mRNA vaccines being the predominant vaccine type. The onset of AIBD ranged from 1 to 123 days post-vaccination, with most patients displaying favorable outcomes and showing improvement or resolution from 1 week to 8 months after treatment initiation. Conclusions: Both new-onset AIBD and exacerbation of pre-existing AIBD may occur following COVID-19 vaccination. Healthcare practitioners should be alert, and post-vaccination monitoring may be essential.

show abstract

Section: Treatment and Outcomes For New-onset Aibd Or Aibd Flaresmentioning

confidence: 99%

New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review

Wu,

Huang,

Wang

et al. 2024

Vaccines

View full text Add to dashboard Cite

show abstract

Tozinameran

2022

Reactions Weekly

View full text Add to dashboard Cite

Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine

et al. 2023

View full text Add to dashboard Cite

Autoimmune bullous diseases (AIBDs) are a heterogeneous group of life-threatening disorders associated with subepidermal or intraepidermal blistering. Skin barrier alterations and prolonged immunosuppressive treatments increase the risk of infections in patients with AIBDs, who are considered fragile. COVID-19 pandemic had a heavy impact on these patients. Although advances have been made in terms of prevention and treatment of COVID-19, this topic remains significant as the pandemic and its waves could last several years and, so far, a relevant proportion of the population worldwide is not vaccinated. This review is a 2022 update that summarizes and discusses the pandemic’s burden on AIBD patients mainly considering relevant studies in terms of: (i) sample dimension; (ii) quality of control populations; (iii) possible standardization by age, gender and country. The findings show that: (i) the risk of COVID-19 infection and its severe course were comparable in AIBD patients and in the general population, except for rituximab-treated patients that presented a higher risk of infection and severe disease; (ii) the mortality rate in COVID-19-infected bullous pemphigoid patients was higher than in the general population, (iii) 121 cases of AIBD onset and 185 cases of relapse or exacerbation occurred after COVID-19 vaccination and a causal relationship has not been demonstrated so far. Altogether, acquired knowledge on COVID-19 pandemic could also be important in possible, albeit undesirable, future pandemic scenarios.

show abstract

A new eruption of bullous pemphigoid following mRNA COVID-19 vaccination

Cited by 3 publications

References 12 publications

New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review

New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review

Tozinameran

Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine

Contact Info

Product

Resources

About